Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebacin for persistent high-risk HPV infection and cervical lesions
ChiCTR2100044295Phase 4Recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Jun 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of rebacin in human papillomavirus infection (4 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoints: HPV cure rate, HPV response rate and 1 more. Started Jun 2017; status: recruiting.
02
Drugs
rebacin
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on ChiCTR2100044295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044295.